How much does losartan typically lower systolic and diastolic blood pressure (in mm Hg)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 24, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Blood Pressure Reduction with Losartan

Losartan 50-100 mg once daily typically lowers blood pressure by approximately 5.5-10.5 mmHg systolic and 3.5-7.5 mmHg diastolic at trough (24 hours post-dose), with peak effects (6 hours post-dose) being moderately larger. 1

Monotherapy Effects

Standard Dosing (50-100 mg once daily)

  • Losartan 50-100 mg once daily produces statistically significant mean blood pressure reductions of 5.5-10.5/3.5-7.5 mmHg compared to placebo 1
  • The 150 mg dose provides no greater effect than 50-100 mg, establishing an effective ceiling dose 1
  • Twice-daily dosing at 50-100 mg/day produces consistently larger trough responses than once-daily dosing at the same total dose 1

Ambulatory Blood Pressure Monitoring Data

  • By 24-hour ambulatory monitoring, losartan 50 mg once daily reduces blood pressure by 9.2/6.9 mmHg 2
  • Losartan 100 mg once daily reduces blood pressure by 9.9/6.4 mmHg 2
  • Losartan 50 mg twice daily reduces blood pressure by 13.2/8.5 mmHg 2

Trough-to-Peak Ratio

  • The trough-to-peak ratio ranges from 50-95% for systolic and 60-90% for diastolic responses, indicating sustained 24-hour efficacy 1
  • Peak effects at 6 hours are uniformly but moderately larger than trough effects at 24 hours 1

Combination Therapy with Hydrochlorothiazide

Enhanced Efficacy

  • Adding hydrochlorothiazide 12.5 mg to losartan 50 mg once daily produces placebo-adjusted blood pressure reductions of 15.5/9.2 mmHg 1
  • This combination provides clinically meaningful additional reductions compared to losartan monotherapy 2

African American Population

  • In African American patients, losartan monotherapy (50-150 mg) reduces blood pressure by 6.4/6.6 mmHg compared to placebo 3
  • The losartan/HCTZ combination produces reductions of 16.8/10.8 mmHg in this population, significantly greater than monotherapy 3

Pediatric Population

  • In children weighing <50 kg, doses of 25-50 mg daily reduce diastolic blood pressure by 5-6 mmHg more than the lowest dose (2.5 mg) 1
  • In children weighing ≥50 kg, doses of 50-100 mg daily produce similar 5-6 mmHg additional reductions compared to the 5 mg dose 1
  • The lowest doses (0.07 mg/kg average) do not offer consistent antihypertensive efficacy 1

Dose-Response Considerations

Suboptimal Dosing

  • The commonly prescribed dose of losartan 50 mg daily appears inferior to ACE inhibitors for mortality reduction in heart failure 4
  • The optimal dose for heart failure (150 mg daily) is higher than that approved in the US for any cardiovascular indication 4
  • Doses used for hypertension (typical range) are lower than target doses demonstrated in heart failure trials 4

Clinical Practice vs. Trial Data

  • The most dramatic blood pressure decreases with ARBs occur with the low starting dose, with subsequent dosing increments producing comparatively smaller changes 4
  • Medium-range doses do not necessarily provide most of the benefits of target doses, as higher doses have provided greater benefits in clinical trials 4

Race and Age Considerations

  • Losartan is effective in reducing blood pressure regardless of race, though the effect is somewhat less in Black patients (typically a low-renin population) 1
  • Men and women, and patients over and under 65 years, show generally similar responses 1
  • In pediatric patients, no significant differences in antihypertensive effect were detected by age (<12 vs ≥12 years) or gender 1

Comparative Context

LIFE Study Data

  • In the LIFE echocardiographic substudy, losartan demonstrated superior left ventricular mass reduction (21.7 g/m²) compared to atenolol (17.7 g/m²) 5
  • Blood pressure reductions were similar between losartan and atenolol groups in this trial 6

References

Related Questions

Does losartan (angiotensin II receptor blocker) lower diastolic blood pressure in hypertensive adults?
A patient on losartan 100 mg daily has persistently elevated blood pressure in the 140–180 mm Hg range; what is the next step in management?
Can losartan be taken every other day instead of once daily?
Is increasing losartan (angiotensin II receptor antagonist) to 50 mg twice daily (bid) more effective than 100 mg once daily for blood pressure control?
A patient is taking losartan potassium 50 mg daily but still has blood pressure of 180/110 mmHg; should the losartan dose be increased or should another antihypertensive medication be started?
What is the appropriate aspirin dosing regimen (high‑dose then low‑dose) for a child with Kawasaki disease to prevent cardiac complications, including weight‑based doses and age considerations?
What symptoms are expected from L2‑L3 severe disc height loss with mixed Modic type I/II end‑plate changes and disc desiccation, a left‑eccentric mild diffuse disc bulge with a small right annular disc extrusion that has migrated superiorly 4 mm and indents the right ventral thecal sac, and moderate left and mild right neuroforaminal narrowing?
How can creatine phosphokinase (CPK) and lactate dehydrogenase (LDH) levels help differentiate hepatic transaminitis from muscle‑related causes of elevated AST and ALT?
In a patient with symptomatic neurogenic orthostatic hypotension who is already taking metoprolol, is it safe to start Northera (droxidopa) and how should the combination be managed?
I am taking losartan and experiencing dizziness, light‑headedness, blurry vision, fatigue, and nausea on standing; could this be orthostatic hypotension and how should I manage it?
How should a patient with nephrocalcinosis be evaluated and managed?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.